Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Guidance on Placement of Integrated Effectiveness and Safety Summaries;Advice from FDA on Presenting Risk Information;More Warnings for Erlotinib;Sanofi-Aventis Said to Overstate Efficacy of Docetaxel;Possible Dosage Alterations for Rituximab;FDA Establishes Transparency Task Force;Unauthorized Clinical Trials Alleged;FDA Should Release Information on Unapproved Uses;Pegylated Anti-TNF Product Closer to European Approval;Viral Contaminant Reducing Supplies of Replacement Enzymes;First Follow-On Biologic Approved in Japan;More Human Embryonic Stem Cell Lines May Be Approved for Research;All Genetic Tests and Performance Data Should Be Registered;Early Development of Biologics to Gain New Regulatory Body in India;Rapid Test for C. diff. Approved;Label Changes for Immunosuppressives Reflect Concern About Kidney Virus